Clene Secures Third-Year NIH Subaward for ALS Program

An announcement from Clene ( (CLNN) ) is now available.

On March 13, 2026, Clene entered into a third-year subaward agreement with New York University for up to $8.0 million under a previously announced four-year, $45.1 million National Institutes of Health grant supporting an Expanded Access Program for CNM-Au8 in amyotrophic lateral sclerosis. The funds, covering the period from September 1, 2025 to August 31, 2026, will be reimbursed based on invoicing, the agreement is terminable on 30 days’ notice by either party, and Clene preserves full control over its background intellectual property, requiring confidentiality safeguards before sharing any proprietary data.

The most recent analyst rating on (CLNN) stock is a Buy with a $48.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.

Spark’s Take on CLNN Stock

According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.

The score is held down primarily by very weak financial performance (minimal and declining revenue, large ongoing losses, negative equity and continued cash burn). Technicals also reflect a bearish trend with weak momentum. Offsetting factors include positive corporate developments (financing that extends runway and FDA engagement around biomarker-driven regulatory strategy), but they do not yet resolve the underlying financial risk.

To see Spark’s full report on CLNN stock, click here.

More about Clene

Clene Inc., through its subsidiary Clene Nanomedicine, operates in the biopharmaceutical industry, focusing on nanomedicine therapies such as CNM-Au8 for neurodegenerative diseases. The company targets conditions like amyotrophic lateral sclerosis, pursuing collaborations with academic and clinical partners to expand patient access to its treatments.

Average Trading Volume: 87,657

Technical Sentiment Signal: Sell

Current Market Cap: $70.14M

See more insights into CLNN stock on TipRanks’ Stock Analysis page.